Caitlin Rausch

31PUBLICATIONS

68CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)AutoimmunityHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical virology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (31)

Sort by Publication Date:

|Jun 27, 2026

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

|May 17, 2026

Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.

|Apr 26, 2026

Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis.

|Apr 26, 2026

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

|Apr 24, 2026

Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

|Oct 22, 2025

Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia.

Naszrin Arani, Caitlin R Rausch, Alexis Geppner

Pageof 6

Frequent Collaborators

21 joint publications

Tapan M Kadia

20 joint publications

Hagop M Kantarjian

17 joint publications

Courtney DiNardo

15 joint publications

Naval G Daver

13 joint publications

Elias Jabbour

13 joint publications

Farhad Ravandi

12 joint publications

Nicholas Short

11 joint publications

Koji Sasaki